Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model

Kidney International

Volumn 69, Issue 11, 2006, Pages 1954-1960

  Kelly, D J ^a   Zhang, Y ^a   Cox, A J ^a   Gilbert, R E ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Glomerulosclerosis; Tranilast; Transforming growth factor ; Tubular atrophy; Tubulointerstitium

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; SMAD2 PROTEIN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG POTENTIATION; ENZYME INHIBITION; GLOMERULOSCLEROSIS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY STRUCTURE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEINURIA; RAT; REMNANT KIDNEY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTHRANILIC ACIDS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBROSIS; KIDNEY; KIDNEY DISEASES; MALE; PERINDOPRIL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33745239220     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000376     Document Type: Article

References (48)

1. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
2. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601-1608.
3. Bohle A, Wehrmann M, Bogenschutz O et al. The pathogenesis of chronic renal failure in diabetic nephropathy: investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991; 187: 251-259.
4. Risdon RA, Sloper JC, de Vardener HE. Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerulonephritis. Lancet 1968; ii: 363-366.
5. Border WA, Brees D, Noble NA. Transforming growth factor-beta and extracellular matrix deposition in the kidney. Contrib Nephrol 1994; 107: 140-145.
6. Benigni A, Zoja C, Corna D et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14: 1816-1824.
7. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice (see comments). Proc Natl Acad Sci USA 2000; 97: 8015-8020.
8. Border WA, Noble NA, Yamamoto T et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992; 360: 361-364.
9. McGowan TA, Zhu Y, Sharma K. Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Curr Diab Rep 2004; 4: 447-454.
10. Shigeki S, Murakami T, Yata N et al. Treatment of keloid and hypertrophic scars by iontophoretic transdermal delivery of tranilast. Scand J Plast Reconstr Surg Hand Surg 1997; 31: 151-158.
11. Mifsud S, Kelly DJ, Qi W et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron 2003; 95: 83-91.
12. Kelly DJ, Zhang Y, Gow R et al. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 2004; 15: 2619-2629.
13. Mifsud S, Kelly DJ, Qi W et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003; 95: p83-p91.
14. Miyajima A, Asano T, Yoshimura I et al. Tranilast ameliorates renal tubular damage in unilateral ureteral obstruction. J Urol 2001; 165: 1714-1718.
15. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982; 307: 652-659.
16. Anderson S, Rennke H, Brenner B. Therapeutic advantages of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000.
17. Zatz R, Dunn BR, Meyer TW et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
18. Parving HH, Andersen AR, Smidt UM et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175-1179.
19. Bjorck S, Nyberg G, Mulec H et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) 1986; 293: 471-474.
20. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
21. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
22. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
23. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
24. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364.
25. Border WA, Noble NA. Transforming growth factor-β in tissue fibrosis. New Engl J Med 1994; 331: 1286-1392.
26. Kelly DJ, Cox AJ, Tolcos M et al. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 2002; 61: 31-39.
27. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 1990; 346: 281-284.
28. O'Connor-McCourt MD, Wakefield LM. Latent transforming growth factor β in serum. J Biol Chem 1987; 262: 14090-14099.
29. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000; 14: 627-644.
30. Mifsud SA, Skinner SL, Cooper ME et al. Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats. J Am Soc Nephrol 2002; 13: 684-692.
31. Wilkinson-Berka JL, Gibbs NJ, Cooper ME et al. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol Dial Transplant 2001; 16: 1343-1349.
32. Schainuck LI, Striker GE, Cutler RE et al. Structural-functional correlations in renia disease. Part II. The correlations. Hum Pathol 1970; 1: 631-641.
33. Schelling JR, Cleveland RP. Involvement of Fas-dependent apoptosis in renal tubular epithelial cell deletion in chronic renal failure. Kidney Int 1999; 56: 1313-1316.
34. Schelling JR, Nkemere N, Kopp JB et al. Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest 1998; 78: 813-824.
35. Wu L, Cox A, Roe C et al. Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 1997; 51: 1553-1567.
36. Rossing K, Schjoedt KJ, Jensen BR et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190-1198.
37. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124.
38. Yamada H, Tajima S, Nishikawa T et al. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem (Tokyo) 1994; 116: 892-897.
39. Miyazawa K, Kikuchi S, Fukuyama J et al. Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 1995; 118: 213-221.
40. Pinto YM, Pinto-Sietsma SJ, Philipp T et al. Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 rat. Hypertension 2000; 36: 747-754.
41. Yu L, Border WA, Anderson I et al. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 2004; 66: 1774-1784.
42. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983; 23: 647-655.
43. Soma J, Sugawara T, Huang YD et al. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002; 92: 693-698.
44. Kelly DJ, Hepper C, Zhang Y et al. Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003; 52: 512-518.
45. Kelly DJ, Cox AJ, Gow RM et al. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension 2004; 44: 195-202.
46. Lehr HA, Mankoff DA, Corwin D et al. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997; 45: 1559-1565.
47. Lehr HA, van der Loos CM, Teeling P et al. Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis. J Histochem Cytochem 1999; 47: 119-126.
48. Kakizaki Y, Kraft N, Atkins RC. Differential control of mesangial cell proliferation by interferon-gamma. Clin Exp Immunol 1991; 85: 157-163.